Cyclooxygenase-2 inhibitors and cardiovascular risk

Current Opinion in Cardiology

Volumn 21, Issue 6, 2006, Pages 613-617

  Solomon, Scott D ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular risk; Cyclooxygenase 2 inhibitors; Nonsteroidal anti inflammatory drugs; NSAIDs

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; VALDECOXIB;

ACUTE HEART INFARCTION; ANALGESIA; ARTHRITIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON POLYP; DOSE RESPONSE; DRUG CONTROL; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; HYPERTENSION; PAIN; PRIORITY JOURNAL; REVIEW; STROKE; SUDDEN DEATH;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; PAIN; RISK ASSESSMENT;

EID: 33750326220     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000245740.85829.4f     Document Type: Review

References (29)

1. Marnett LJ, Rowlinson SW, Goodwin DC, et al. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J Biol Chem 1999; 274:22903-22906.
2. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase Inhibition and Cardiovascular Risk. Circulation 2005; 112:759-770. This is an excellent recent review on cardiovascular risk associated with coxibs.
3. Foegh M, Ramwell P. The eicosanoids: prostaglandins, thromboxanes, leukotrienes, and related compounds. In: Katzung BG, editor. Basic and Clinical Pharmacology. 9th ed. New York, NY: Lange Medical Books/McGraw-Hill; 2004.
4. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345:433-442.
5. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351:1709-1711.
6. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96:272-277.
7. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004; 44:140-145.
8. Whelton A, White WB, Bello AE, et al., SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90:959-963.
9. Sowers JR, White WB, Pitt B, et al., Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-h blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165:161-168.
10. Izhar M, Alausa T, Folker A, et al. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension 2004; 43:573-577.
11. White WB, Kent J, Taylor A, et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39:929-934.
12. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109:2068-2073.
13. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142:157-164.
14. Summary for patients in Ann Intern Med 2005; 142:I21.
15. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective nonsteroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365:475-481. This describes an important observational study of cardiovascular risk associated with coxibs.
16. Bombardier C, Laine L, Reicin A, et al., VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520-1528.
17. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al. "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis". N Engl J Med 2006; 343:1520-1528.
18. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Engl J Med 2006; 354:1193.
19. Farkouh ME, Kirshner H, Harrington RA, et al., TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364:675-684.
20. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113:1578-1587. This observational study implicated traditional NSAIDs in cardiovascular risk in a large cohort of women.
21. Bresalier RS, Sandler RS, Quan H, et al., Adenomatous Polyp Prevention on Vioxx (APPROVE) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-102. Erratum in N Engl J Med 2006; 355:221. This is a report of the APPROVE trial which was stopped early and led to the withdrawal of rofecoxib.
22. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-1952.
23. Lagakos SW. Time-to-event analyses for long-term treatments - the APPROVE trial. N Engl J Med 2006; 355:113-117.
24. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081-1091.
25. Solomon SD, McMurray JJ, Pfeffer MA, et al., Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080. This is a report of the cardiovascular risk associated with two doses of celecoxib in a randomized placebo controlled trial. This was the first placebo-controlled data demonstrating an increased cardiovascular risk with celecoxib.
26. Levin B. Celecoxib in adenoma prevention: The PreSAP Trial. FDA Advisory Committee on Cox-2 Inhibitors and NSAIDs. 16-18 February 2005. Gaithersburg: FDA. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4090S1_09_FDA-Levin.PPT. [Accessed: 16 August 2006]
27. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113:1950-1957.
28. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873-884.
29. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885-995.